Table 1 Baseline characteristics of patients.
From: PDZK1 inhibits MRP2-mediated oxaliplatin chemosensitivity in hepatocellular carcinoma
Parameters | Total (n = 39) | Non-recurrence (n = 21) | Recurrence (n = 18) | P value |
|---|---|---|---|---|
Demographic parameters | ||||
Age (years), mean ± SD | 63.1 ± 10.7 | 67.4 ± 9.6 | 57 ± 9 | < 0.001*** |
Male sex, n(%) | 32 (82.1%) | 17 (81%) | 15 (83.3%) | 0.847 |
TNM-stage, n(%) | ||||
I, II | 16 (33.3%) | 12 (57.1%) | 4 (22.2%) | 0.027* |
III, IV | 23 (66.7%) | 9 (42.9%) | 14 (77.8%) | |
AFP (ng/ml), n(%) | ||||
< 200 | 23 (66.7%) | 14 (66.7%) | 9 (50%) | 0.291 |
> 200 | 16 (33.3%) | 7 (33.3%) | 9 (50%) | |
Hepatitis B virus, n(%) | ||||
Positive | 24 (61.5%) | 9 (42.9%) | 15 (83.3%) | 0.01* |
Negative | 15 (38.5%) | 12 (57.1%) | 3 (16.7%) | |
Tumor grade, n(%) | ||||
G1, G2 | 19 (48.7%) | 12 (57.1%) | 7 (38.8%) | 0.906 |
G3 | 3 (7.7%) | 2 (9.6%) | 1 (5.6%) | |
Gx | 17 (43.6%) | 7 (33.3%) | 10 (55.6%) | |
